« Back to Record
Citation APA

Harbeck, N., Jassem, J., Zhang, Q., Im, Y. H., Wojtukiewicz, M., Sun, Q., Chen, S.-C., Goeldner, R. G., Uttenreuther-Fischer, M., Xu, B., Piccart-Gebhart, M., Huang, C. S., Hurvitz, S., Yeh, D. C., Shao, Z., Im, S. A., Jung, K. H., Shen, K., & Ro, J. (2016). Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial. Lancet oncology, 17(3), 357-366. doi:10.1016/S1470-2045(15)00540-9


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/231576

Harbeck, N., Jassem, J., Zhang, Q., Im, Y. H., Wojtukiewicz, M., Sun, Q., Chen, S.-C., Goeldner, R. G., Uttenreuther-Fischer, M., Xu, B., Piccart-Gebhart, M., Huang, C. S., Hurvitz, S., Yeh, D. C., Shao, Z., Im, S. A., Jung, K. H., Shen, K., & Ro, J. (2016). Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial. Lancet oncology, 17(3), 357-366. doi:10.1016/S1470-2045(15)00540-9